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Abstract
Background: The tracheobronchomalacia is a life-threatening complication of mucopolysaccharidosis (MPS)
without known effective, optimal treatment. The severe expiratory collapse of the trachea and bronchi is one of
causes of the high rate of deaths in the course of airway impairment in MPSII patients.
Case presentation: Due to the adynamic tracheobronchomalacia despite of enzymatic treatment (ERT) in our
MPSII patient, a life-saving tracheal bifurcated type-Y endoprosthesis (a self-expanding, metal stent for the
prosthesis of tracheal and bronchial stenosis) was implanted. In the followed months, the breathing efficiency
improved, but then gradual worsening, progression of bronchi occlusion at the stent border resulted in patient’s
death.
Conclusion: The Y-stent implantation appears to be a short-term, life-saving solution without satisfactory long-term
effects due to the progress of peripheral bronchomalacia and increased tissue proliferation and granulation, that
arises during the illness’ course.
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Background
The treatment for tracheobronchomalacia (TBM) is a
challenging problem in mucopolysaccharidosis type II
(MPSII) patients [1]. We present the short lasting thera-
peutic effect ended up with a rapid deterioration of re-
spiratory function, after the tracheal endoprosthesis
type-Y implantation in an adult MPSII patient.
Case presentation
30-year-old MPSII (OMIM: 309900) patient diagnosed
in childhood. Due to delayed psycho-motor develop-
ment, stiffness of joints mainly in the upper limbs and
bilateral inguinal hernias. The increased urine glycos-
aminoglycans (GAGs) excretion and later the hemizy-
gous mutation (c.1035G > T, p.W345C) result confirmed
clinical diagnosis. In the course of the underlying dis-
ease, the thickening of voice folds and persistent hoarse-
ness without respiratory distress developed. Spirometry
examination confirmed a mild restrictive ventilatory de-
fect and a reduced total lung capacity. At the age of 26
an enzyme replacement therapy (ERT, idursulfase) was
introduced with a good clinical effect.
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During the fourth year of ERT, after a viral infection
of the respiratory tract, the patient reported cough and
exercise-related dyspnea. A phoniatric examination re-
vealed swallowed mucosa and a polyp structure on the
right vocal fold. Due to the inflammatory aetiology, ster-
oidotherapy (methylprednisolone) was commenced with
a long-acting, selective, H1-receptor antagonist (bilas-
tine); resulting in a clinical improvement. After 4 months
the symptoms recurrence with a worsening of the spir-
ometry tests results occurred. The patient suffered from
shortness of breath and attacks of unproductive, night-
time cough. The computed tomography scan performed
during the phonation and Valsalva test, revealed: a con-
centric soft tissue hypertrophy of the upper and middle
laryngeal part with a reduction of lumen diameter -stat-
ing an adynamic tracheobronchomalacia. (Fig. 1). La-
boratory tests confirmed a partially compensated
respiratory acidosis (pH: 7.310 [7.350–7.450], pCO2:
56.5 mmHg [35–48], pO2: 67.6 mmHg [83–108],
HCO3act: 29 mmol/l [22–28], BE(B) c (ABE): 2.9 mmol/l
[− 2.0–3.0], sO2: 75.9% [95.0–99.0]). Patient refused con-
tinuous positive airway pressure (CPAP) therapy.
Due to the deteriorating condition despite conservative
treatment, patient was qualified for the bifurcated tra-
cheobronchial, Y-stent implantation. The procedure of
housing the stent was complicated by the larynx and
lower airways oedema, and required tracheostomy. The
self-expanding, metal stent for the prosthesis of tracheal
and bronchial stenoses was placed through the tracheos-
tomy opening, producing a combination of tracheostomy
and bifurcated-tracheobronchial stent.
The patient’s breath efficiency significantly improved:
pH: 7.385, pCO2: 43.5 mmHg, pO2: 84.7 mmHg,
HCO3act: 26.4 mmol/l, BE: 0.4 mmol/l, sO2: 95.4%. Im-
aging studies confirmed the effective dilation of patient’s
airways (Fig. 2). Unfortunately 3 weeks later, patient’s
status deteriorated. The new stenosis of the major bron-
chus, caused by tissue granulation and bronchomalacia
distally from the prosthesis, was stated. The granular
material was coagulated using argon plasma, resulting
with the clinical improvement. The ERT, once a week,
was continued during the whole time, as well as respira-
tory regimen at home (nebulizers, aspirations).
Two months after leaving the hospital, during the
tracheostomy tube toilet, patient suffered from severe
dyspnea (sO2 < 60%). The unconscious patient was
transported to a district hospital. Two episodes of a
cardiac arrest followed by asystole appeared, with sub-
sequent effective resuscitation procedures. After a
third cardiac arrest in pulseless-electrical-activity
mechanism and non-effective CRP the patient’s death
was declared.
Fig. 1 Computed tomography of the respiratory tract in MPSII patient with respiratory insufficiency. The computed tomography (CT) scan
performed during the phonation and Valsalva test, revealed: an adynamic tracheobronchomalacia in the lower parts of the respiratory tract with a
deformation and significant reduction of the respiratory pathway diameters. The deformed trachea had reduced sagittal dimension with a
reduction of lumen in a distance of at least few centimetres, at its narrowest point to 0,4cm2, 4,5 × 9 mm. a) A significant reduction in the airway
lumen observed in the MPS patient - multilevel tracheomalacia with excessive collapsibility of the trachea. b) Bronchomalacia with a significant,
multilevel reduction in the peripheral airway lumen
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Discussion and conclusions
The guidelines do not give clear recommendations how
to treat a severe respiratory failure in MPSII patient [2].
The article describes the sudden respiratory decompen-
sation in a MPS patient due to adynamic TBM followed
by a severe tissue granulation at the border of implanted
respiratory Y-stent.
The limitation of this report is the fact that it is the
single-centre observation however, it presents a case
where the rare occurrence of the disease (1:100 up to
150,000 male births) per se, limits the clinical experience
of the centres, especially when it refers to the adult
MPSII patients.
The severe expiratory collapse of the trachea and
bronchi can explain the high rate of deaths caused by
airway impairment in MPSII patients [3, 4].
The severe obstructive respiratory symptoms develop
mainly in MPS I, II and VI [1, 5–7]. It is known that
ERT is more effective in preventing the upper airway ob-
struction, penetrating to the bronchi soft tissue but not
to the trachea cartilaginous skeleton [6] thus does not
prevent the bronchomalacia [6].
The TBM causes difficulties during intubation and
stent implantation and may require external access to
the airways. Despite a relatively short-term improve-
ment; stent implantation may even accelerate the se-
quence of events that finally lead to a patient’s death.
The increased tissue granulation and mucus production,
causing the airway obstruction, observed on the Y-stent
border, could have resulted from the irritating role of
the prosthesis on the mucosa respiratory tissues. A simi-
lar phenomenon was observed in the implanted coron-
ary stent, leading to the restenosis [8]. Our article draws
attention to two problems: the severe morbidity (an
acute complication during intubation) [9, 10] and the
mortality of MPSII patients after a Y-stent implantation.
The positive short-term effect after airway stenting in
MPS II and VI patients, with high long-term morbidity,
was reported [11, 12]. Despite this, authors suggest that
in case of TM with severe tracheal stenosis the stent im-
plementation should be mandatory, life-saving proced-
ure [12]. The main ‘take-away’ lesson of this case report
are the weak sides of this type of therapy, but until now
we do not have the better way of adynamic TBM and re-
spiratory decompensation treatment in MPS.
Clinical reports suggest the advantages of CPAP ther-
apy in respiratory decompensation in MPS [12, 13]. But
such therapy will be most effective in the dynamic TBM
and there is still no optimal model for the treatment of
its adynamic form.
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